How pazopanib/pazopanib is different from other VEGFR inhibitors

Pazopanib As a new generationVEGFR inhibitor, there are certain differences from other common targeted anti-angiogenic drugs in terms of structural mechanism and pharmacodynamic characteristics. Compared with other vascular endothelial growth factor receptor tyrosine kinase inhibitors such as Sorafenib, Sunitinib, and Axitinib, pazopanib exhibits a unique target spectrum and toxicity profile, making it more advantageous in certain clinical scenarios.

First of all, from the perspective of target coverage, pazopanib not only inhibitsVEGFR-1, VEGFR-2 and VEGFR-3, but also acts on multiple key signaling molecules such as PDGFR-α, PDGFR-β and c-Kit. This multi-target mechanism helps to more comprehensively inhibit tumor angiogenesis and stromal support environment. In contrast, the selectivity of axitinib is more concentrated on VEGFR, so drug resistance may be faster in some patients.

Secondly, in terms of drug safety, pazopanib has common adverse reactions such as hypertension, diarrhea, elevated liver enzymes and hair discoloration. Compared with sunitinib, the incidence of bone marrow suppression and hand-foot syndrome is lower, and some patients are better tolerated in long-term treatment. Particularly in the setting of hepatic insufficiency or long-term treatment, pazopanib is considered a relatively mild but highly effective targeted regimen.

Thirdly, pazopanib has a fixed once-daily dosing schedule and does not require the "4-week treatment + 2-week rest" cycle like sunitinib. This helps improve patient compliance and quality of life, which is particularly important in the elderly or patients with chronic diseases.

In addition, in terms of specific clinical data, a head-to-head comparison study of pazopanib and sunitinib was conducted. The results showed that the two had similar tumor control rates, but pazopanib had a better quality of life score. Therefore, in a tumor treatment strategy that emphasizes long-term management, pazopanib has formed a clearly differentiated positioning among VEGFR inhibitors due to its relatively mild side effects and convenient medication administration.

Reference materials:https://www.votrient.com/